Medical technology company TransMedics Group Inc (Nasdaq: TMDX) announced on Monday that it has entered into a strategic collaboration with automotive company Mercedes-Benz Group AG to establish Italy's first dedicated ground transportation network for organ transplantation.
A fleet of purpose-built Mercedes-Benz V-Class vehicles will be deployed across four National OCS Program hubs in Milan, Rome, Padua and Bari to support the use of TransMedics' Organ Care System (OCS) perfusion technology. The initiative aims to increase donor organ utilisation and expand access to transplantation.
The Italian network is expected to launch before the end of 2025, with each hub equipped with OCS Lung, Heart and Liver Systems and staffed by clinical perfusionists. Operations will be coordinated from TransMedics' National Command Center in Santa Giulia, Milan.
The partnership forms part of TransMedics' strategy to replicate its U.S. NOP model in Europe by integrating dedicated ground and air logistics with its OCS platform and clinical services, laying the groundwork for a multi-country transplant logistics network.
Summit Therapeutics expands ivonescimab programme into bladder cancer with Phase II/III trial
Lilly secures FDA Breakthrough Therapy designation for olomorasib in pancreatic cancer
Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation
Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas
Datroway approved in EU for first-line metastatic triple-negative breast cancer
10x Genomics and Lausanne University Hospital to collaborate on cancer care research
BeOne Medicines expands US manufacturing with USD300m investment
GSK's Jideytro (zidesamtinib) gains US approval for previously treated ROS1-positive NSCLC
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
Insilico initiates Rentosertib Phase III clinical trial for idiopathic pulmonary fibrosis
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer
Abbisko Therapeutics and AstraZeneca collaborate to conduct combination clinical trial for NSCLC